In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors

Fundamental and Clinical Pharmacology

Volumn 29, Issue 6, 2015, Pages 604-614

  Ollier, Edouard ^a,b,c   Hodin, Sophie ^b   Basset, Thierry ^a,b   Accassat, Sandrine ^a,b,d   Bertoletti, Laurent ^a,b,d   Mismetti, Patrick ^a,b,d   Delavenne, Xavier ^a,b,d  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b University Jean Monnet of Saint Etienne EA3065   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Bioavailability; Caco 2; Dabigatran; Omeprazole; Pharmacokinetics; Population model; Proton pump inhibitors; Rabeprazole

Indexed keywords

CYCLOSPORIN A; DABIGATRAN ETEXILATE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; CYCLOSPORIN; DABIGATRAN; MULTIDRUG RESISTANCE PROTEIN; PROTON PUMP INHIBITOR; THROMBIN;

ADULT; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; THROMBIN TIME; CACO-2 CELL LINE; DRUG INTERACTION; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; CACO-2 CELLS; CELL LINE, TUMOR; CYCLOSPORINE; DABIGATRAN; DRUG INTERACTIONS; HUMANS; LANSOPRAZOLE; MALE; OMEPRAZOLE; P-GLYCOPROTEIN; PROTON PUMP INHIBITORS; RABEPRAZOLE; THROMBIN; YOUNG ADULT;

EID: 84983113554     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12154     Document Type: Article

References (29)

1. Salem J.E., Sabouret P., Funck-Brentano C., Hulot J.S. Pharmacology and mechanisms of action of new oral anticoagulants. Fundam. Clin. Pharmacol. (2015) 29 10-20.
2. Delavenne X., Ollier E., Basset T. et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br. J. Clin. Pharmacol. (2013) 76 107-113.
3. ®) after comedication with verapamil in healthy subjects. Br. J. Clin. Pharmacol. (2013) 75 1053-1062.
4. Härtter S., Koenen-Bergmann M., Sharma A. et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br. J. Clin. Pharmacol. (2012) 74 490-500.
5. Pauli-Magnus C., Rekersbrink S., Klotz U., Fromm M.F. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. (2001) 364 551-557.
6. Stangier J., Stähle H., Rathgen K., Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet. (2008) 47 47-59.
7. Stangier J., Eriksson B.I., Dahl O.E. et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol. (2005) 45 555-565.
8. Gnoth M.J., Buetehorn U., Muenster U., Schwarz T., Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J. Pharmacol. Exp. Ther. (2011) 338 372-380.
9. European Medicines Agency. Guideline on the investigation of drug interactions. Final CPMP/EWP/560/95
10. Delavenne X., Moracchini J., Laporte S., Mismetti P., Basset T. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J. Pharm. Biomed. Anal. (2012) 58 152-156.
11. Love J.E., Ferrell C., Chandler W.L. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb. Haemost. (2007) 98 234-242.
12. Troconiz I.F., Tillmann C., Liesenfeld K.H., Schäfer H.G., Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J. Clin. Pharmacol. (2007) 47 371-382.
13. Lixsoft-Incuballiance: Monolix User Guide Version 4.3.2. http://www.lixoft.eu/wp-content/resources/docs/UsersGuide.pdf, 2012. (last accessed 27/01/2015)
14. Kuhn E., Lavielle M. Coupling a stochastic approximation version of EM with an MCMC procedure. ESAIM Probab. Stat. (2004) 8 115-131.
15. Samson A., Lavielle M., Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput. Stat. Data Anal. (2006) 51 1562-1574.
16. Wickham H. ggplot2: elegant graphics for data analysis. Springer, New York, 2009.
17. R Development Core Team R: A language and environment for statistical computing. (2013). R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org. (last accessed 27/01/2015)
18. Weiss M., Sermsappasuk P., Siegmund W. Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition. J. Clin. Pharmacol. (2012) 52 381-387.
19. Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. (2008) 36 386-399.
20. Holford N.H. The visual predictive check superiority to standard diagnostic (Rorschach) plots. Population Approach Group in Europe (PAGE), Pamplona, Spain, 2005. Available from www.page-meeting.org/?abstract=738. (last accessed 27/01/2015)
21. Xia C.Q., Liu N., Yang D., Miwa G., Gan L.S. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab. Dispos. (2005) 33 637-643.
22. Schwab D., Fischer H., Tabatabaei A., Poli S., Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J. Med. Chem. (2003) 46 1716-1725.
23. Lavielle M., Mbogning C. An improved SAEM algorithm for maximum likelihood estimation in mixtures of non linear mixed effects models. Stat. Comput. (2014) 24 693-707.
24. Mead R. A generalised logit-normal distribution. Biometrics (1965) 21 721-732.
25. Muenster U., Grieshop B., Ickenroth K., Gnoth M.J. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm. Res. (2008) 25 2320-2326.
26. Ishiguro N., Kishimoto W., Volz A., Ludwig-Schwellinger E., Ebner T., Schaefer O. Impact of endogenous esterase activity on in vitro P-glycoprotein profiling of dabigatran etexilate in caco-2 monolayer. Drug Metab. Dispos. (2014) 42 250-256.
27. CMHP assessment report for pradaxa, Procedure No. EMEA/H/C/829. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf. (last accessed 27/01/2015)
28. Eriksson B.I., Dahl O.E., Ahnfelt L. et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb. Haemost. (2004) 2 1573-1580.
29. Chan N.C., Coppens M., Hirsh J. et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J. Thromb. Haemost. (2015) 13 353-359. [Epub ahead of print]